.png){kind=icon}
Return
Type 2 diabetes
.png){kind=icon}
PRE
AI
DOI：10.1016/S0140-6736(22)01655-5.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes worldwide. The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). Early detection and proactive management are crucial for prevention and mitigation of microvascular and macrovascular complications and mortality burden. Access to novel therapies improves person-centred outcomes beyond glycaemic control. Precision medicine, including multiomics and pharmacogenomics, hold promise to enhance understanding of disease heterogeneity, leading to targeted therapies. Technology might improve outcomes, but its potential is yet to be realised. Despite advances, substantial barriers to changing the course of the epidemic remain. This Seminar offers a clinically focused review of the recent developments in type 2 diabetes care including controversies and future directions.
Keywords:
LIFE-STYLE INTERVENTION
OBSTRUCTIVE SLEEP-APNEA
INSULIN PUMP THERAPY
GLYCEMIC CONTROL
DOUBLE-BLIND
CARDIOVASCULAR-DISEASE
PHYSICAL-ACTIVITY
WEIGHT-LOSS
TREATMENT SATISFACTION
CARDIOMETABOLIC RISK
Journal
IF:
88.5
Papers:
5.4W
Citations:
34.8W
Organization
Cited Papers
ShareSavePreparation and characteristics of cellulose nanowhisker reinforced acrylic foams synthesized by freeze-casting.png)
RSC Advances
RSC AdvancesIF0
PREAI
ShareSaveCollateral Damage of the COVID-19 Pandemic on Nutritional Quality and Physical Activity: Perspective from South KoreaOBESITY
OAAI
OBESITYIF4.7
OAAIShareSaveOnce-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trialLANCETOAAI
LANCETIF88.5
OAAIShareSaveEffects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonistCELL METABOLISM
OAAI
CELL METABOLISMIF30.9
OAAIShareSaveThe Lancet Commission on diabetes: using data to transform diabetes care and patient livesLANCET
LANCETIF88.5
PREAI
ShareSaveShareSave
View more